• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA strengthens warning that NSAIDs increase heart attack and stroke risk
Back in 2005, the FDA warned that taking nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen increased the risk of having a heart attack or stroke. Last week it took the unusual step of further strengthening this warning. This was done on the advice of an expert panel that reviewed new information about NSAIDs and their risks. Because NSAIDs are widely used, it’s important to be aware of downsides of taking an NSAID and to take steps to limit the risk. Many people take NSAIDs to relieve mild to moderate pain. These medications may be particularly effective in conditions in which pain results pri...
Source: New Harvard Health Information - July 13, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Heart Health heart attack heart disease NSAIDS Stroke Source Type: news

Risk of Hemorrhagic Stroke in Patients Exposed to Nonsteroidal Anti-Inflammatory Drugs: A Meta-Analysis of Observational Studies
Conclusion: Our results indicated that the use of NSAIDs is significantly associated with a higher risk of developing hemorrhagic stroke. These results should be interpreted with caution because they may be confounded owing to the observational design of the individual studies. Nevertheless, we recommend that NSAIDs should be used judiciously, and their efficacy and safety should be monitored proactively.Neuroepidemiology 2018;51:166 –176
Source: Neuroepidemiology - September 2, 2018 Category: Epidemiology Source Type: research

Common Painkiller Linked To Heart Attack And Stroke, UK Warning
Common painkiller, diclofenac, raises the risk of heart attack and stroke among patients with serious underlying heart conditions, the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has warned. MHRA specifies that patients with circulatory problems, heart disease, heart failure, or a previous stroke or heart attack should stop using diclofenac. Diclofenac is known under several trade names, including Diclomax, Defenac, Diclofex, Dyloject, Econac, Enstar, Flamrase, Flamatak, Motifene, Rheumatac, Rhumalgan, Volsaid, and Voltarol...
Source: Health News from Medical News Today - July 1, 2013 Category: Consumer Health News Tags: Pain / Anesthetics Source Type: news

COX-2 Inhibitors Linked to Stroke Mortality COX-2 Inhibitors Linked to Stroke Mortality
New data show the previously reported increased risk for cardiovascular events with these pain meds includes increased stroke death; risk was driven by older drugs, such as etodolac and diclofenac. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - November 6, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

High-dose painkiller heart risk: small but significant
Conclusion This large review adds to, and expands on, the current evidence on the risks of vascular disease and gastrointestinal complications for different NSAIDs. It largely concentrates on trials of high doses of NSAIDs that can only be prescribed by a doctor. It is unclear from this study whether there is any risk from taking lower doses available over the counter. While most experts advise that low-dose NSAIDs, taken occasionally, are safe for most people, an accompanying editorial points out that there are still “large gaps” in evidence on the risks with lower doses of NSAIDs. While the risk to individuals is sma...
Source: NHS News Feed - May 30, 2013 Category: Consumer Health News Tags: Medication Heart/lungs Source Type: news

Painkiller increases chance of heart attack, health officials advise
Experts says patients with heart conditions should stop using diclofenac after study finds stroke and heart attack linkHealth officials have advised patients with heart problems to avoid an over-the-counter painkiller used by millions after research found that it can significantly increase the risk of heart attack or stroke.The Medicines and Healthcare products Regulatory Agency (MHRA) said that patients with an underlying heart condition, such as heart failure, heart disease or circulatory problems, or patients who have previously suffered heart attacks or strokes, should no longer use diclofenac.An MHRA spokesman said th...
Source: Guardian Unlimited Science - June 29, 2013 Category: Science Tags: Heart attack The Guardian News Health Society Drugs UK news Science Source Type: news

Uganda: Painkiller 'Diclofenac' Linked to Heart Attack
[New Vision]Diclofenac, a pain killer that increases the risk of heart attack and stroke, is easily accessible across Uganda. Virtually, every drug shop and pharmacy is selling it without prescription.
Source: AllAfrica News: Health and Medicine - February 18, 2013 Category: African Health Source Type: news

Some Pain Drugs Increase the Risk of Heart Attack
ROCHESTER, Minn. — Some of the most common pain drugs used by older adults who experience discomfort in muscles and joints can increase the risk of heart attack and stroke. The April issue of Mayo Clinic Health Letter covers the risks of nonsteroidal anti-inflammatory drugs (NSAIDs) that include celecoxib (Celebrex), diclofenac (Voltaren), ibuprofen (Advil, Motrin [...]
Source: Mayo Clinic Health Information - April 26, 2013 Category: Consumer Health News Source Type: news

Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study
Conclusions The cardiovascular risk associated with NSAID use in RA patients was modest and significantly lower than in non-RA individuals. Moreover, only a few of the individual NSAIDs were associated with increased cardiovascular risk. NSAID use should be assessed in the individual patient based on the indication for pain relief and risk factors for adverse effects, and not automatically be avoided due to concerns of severe cardiovascular outcomes alone.
Source: Annals of the Rheumatic Diseases - July 3, 2014 Category: Rheumatology Authors: Lindhardsen, J., Gislason, G. H., Jacobsen, S., Ahlehoff, O., Olsen, A.-M. S., Ole Rintek Madsen, , Torp-Pedersen, C., Hansen, P. R. Tags: Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology Clinical and epidemiological research Source Type: research

Celecoxib for rheumatoid arthritis.
CONCLUSIONS: Celecoxib may improve clinical symptoms, alleviate pain and contribute to little or no difference in physical function compared with placebo. Celecoxib was associated with fewer numbers of participant withdrawals. Results for incidence of gastroduodenal ulcers (≥ 3 mm) and short-term serious adverse events were uncertain; however, there were few reported events for either.Celecoxib may slightly improve clinical symptoms compared with tNSAIDs. Results for reduced pain and improved physical function were uncertain. Particpants taking celecoxib had lower incidence of gastroduodenal ulcers (≥ 3 mm) and there w...
Source: Cochrane Database of Systematic Reviews - June 9, 2017 Category: General Medicine Authors: Fidahic M, Jelicic Kadic A, Radic M, Puljak L Tags: Cochrane Database Syst Rev Source Type: research

Differences in cardiovascular safety with non ‐steroidal anti‐inflammatory drug therapy ‐ a nationwide study in patients with osteoarthritis
This article is protected by copyright. All rights reserved.
Source: Basic and Clinical Pharmacology and Toxicology - November 28, 2018 Category: Drugs & Pharmacology Authors: Carlo Alberto Barcella, Morten Lamberts, Patricia McGettigan, Emil Loldrup Fosb øl, Jesper Lindhardsen, Christian Torp‐Pedersen, Gunnar Hilmar Gislason, Anne‐Marie Schjerning Olsen Tags: Original Article Source Type: research

Top 20 Research Studies of 2022 for Primary Care Physicians
This article summarizes the top 20 research studies of 2022 identified as POEMs (patient-oriented evidence that matters), excluding COVID-19. Statins for primary prevention of cardiovascular disease produce only a small absolute reduction in a person's likelihood of dying (0.6%), having a myocardial infarction (0.7%), or having a stroke (0.3%) over three to six years. Supplemental vitamin D does not reduce the risk of a fragility fracture, even in people with low baseline vitamin D levels or a previous fracture. Selective serotonin reuptake inhibitors are preferred medical therapy for panic disorder, and patients who disco...
Source: American Family Physician - April 13, 2023 Category: Primary Care Authors: Roland Grad Mark H Ebell Source Type: research

Pages: 1  2  3